| Literature DB >> 33880045 |
Li-Juan Wu1, Yan Luo2, Guo-Lu Shi3, Zhong-Yue Li1.
Abstract
PURPOSE: Nontyphoidal Salmonella (NTS) is a leading bacterial cause for acute gastroenteritis in children. With the increasing use of antibiotics worldwide, antibiotic resistance has become a global problem. However, data on NTS infections and changes in antibiotic resistance among children remain limited in China. We aimed to characterize the prevalence, clinical feature, serotype and the changes of antibiotic resistance of NTS in children in Chongqing.Entities:
Keywords: antibiotic resistance; nontyphoidal Salmonella; pediatric; prevalence
Year: 2021 PMID: 33880045 PMCID: PMC8053510 DOI: 10.2147/IDR.S301318
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Figure 1Distribution of 501 cases of children with nontyphoidal Salmonella infections by month. Y axis: number of cases.
Prevalence, Clinical Features, Laboratory Tests, Serogroup and Serotype in 501 Patients with NTS Infections
| Clinical Data | Number (Percentage) | Clinical Data | Number (Percentage) |
|---|---|---|---|
| Age&Sex | NTS serogroup (n=501) | ||
| <12 months | 225 (49.9%) | Serogroup B | 338 (67.5%) |
| 1–3 years | 200 (39.9%) | Serogroup C | 59 (11.8%) |
| ≥3 years | 76 (15.2%) | Serogroup D | 58 (11.6%) |
| Male/Female | 306/195 (1.5:1) | Serogroup E | 21 (4.2%) |
| Symptoms | Ungrouped | 24 (5%) | |
| Fever (T>37.3°C) | 422 (84.2%) | Polyvalent | 1 (0.2%) |
| Diarrhea | 472 (94.2%) | NTS serotype (n=284) | |
| Vomit | 146 (29.1%) | Typhimurium | 225 (79.2%) |
| Convulsion | 32 (6.4%) | Enteritidis | 27 (9.5%) |
| Abdominal pain | 13 (2.6%) | Derby | 7 (2.5%) |
| Distension | 4 (0.8%) | Stanley | 6 (2.1%) |
| Laboratory studies | Dublin | 5 (1.8%) | |
| Leukocytosis (≥12×109/L) | 183/490 (37.3%) | London | 5 (1.8%) |
| CRP (>8mg/dl) | 280/490 (57.1%) | Aragorn | 2 (0.7%) |
| PCT (>0.05ng/mL) | 315/333 (94.6%) | Newport | 2 (0.7%) |
| Stool culture: positive NTS | 473 (94.4%) | Bovis morbifificans | 1 (0.4%) |
| Blood culture: positive NTS | 39 (7.8%) | Sao Paulo | 1 (0.4%) |
| Pus culture: positive NTS | 2 (0.4%) | Weltevreden | 1 (0.4%) |
| Bone marrow culture: positive NTS | 3 (0.6%) | Anatum | 1 (0.4%) |
| Cerebrospinal fluid culture: positive NTS | 2 (0.4%) |
Antimicrobial Susceptibility Results of NTS Isolated from 501 Patients
| Antibiotics | S (%) | I (%) | R (%) |
|---|---|---|---|
| Amoxicillin/clavulanate potassium (n=143) | 120 (83.9) | 10 (7.0) | 13 (9.1) |
| Ampicillin (n=432) | 74 (17.1) | 1 (0.2) | 357 (82.7) |
| Piperacillin/tazobactam (n=395) | 335 (84.8) | 32 (8.1) | 28 (7.1) |
| Cephazolin (n=441) | 17 (3.9) | 10 (2.3) | 414 (93.8) |
| Cefotaxime (n=294) | 196 (66.7) | 0 (0.0) | 98 (33.3) |
| Ceftriaxone (n=305) | 201 (65.9) | 5 (1.6) | 99 (32.5) |
| Ceftazidime (n=400) | 317 (79.3) | 8 (2.0) | 75 (18.7) |
| Cefepime (n=422) | 319 (75.6) | 15 (3.6) | 88 (20.8) |
| Ertapenem (n=197) | 19 (99.0) | 0 (0.0) | 2 (1.0) |
| Imipenem (n=377) | 374 (99.2) | 0 (0.0) | 3 (0.8) |
| Ciprofloxacin (n=487) | 18 (37.4) | 215 (44.1) | 90 (18.5) |
| Levofloxacin (n=487) | 33 (68.2) | 120 (24.6) | 35 (7.2) |
| Amikacin (n=437) | 25 (5.7) | 1 (0.2) | 411 (94.1) |
| Gentamicin (n=394) | 7 (1.8) | 0 (0.0) | 387 (98.2) |
| Tobramycin (n=226) | 11 (4.9) | 0 (0.0) | 215 (95.1) |
| Compound- sulfamethoxazole (n=398) | 22 (55.8) | 0 (0.0) | 176 (44.2) |
| Aztreonam (n=367) | 25 (68.4) | 4 (1.1) | 112 (30.5) |
| Chloramphenicol (n=172) | 70 (40.7) | 0 (0.0) | 102 (59.3) |
| Tetracycline (n=178) | 45 (25.3) | 0 (0.0) | 133 (74.7) |
Abbreviations: S, sensitive; R, resistant; I, intermediate.
Figure 2Changes of drug resistance in past ten years. Y axis: antibiotic resistance rates (%).
Figure 3The proportion of MDR isolates in each year.
Figure 4The cases of hospitalized children with NTS infections from 2009 to 2018. Y axis: cases of Salmonella infection.
Antimicrobial Susceptibility Profile of Salmonella Typhimurium
| Antibiotics | S (%) | I (%) | R (%) |
|---|---|---|---|
| Chloramphenicol (n=74) | 12 (16.2) | 0 (0.0) | 62 (83.8) |
| Ampicillin (n=180) | 17 (9.4) | 0 (0.0) | 163 (90.6) |
| co Compound sulfamethoxazole (n=149) | 74 (49.7) | 0 (0.0) | 75 (50.3) |
| Pi peracillin/tazobactam (n=146) | 129 (88.4) | 2 (1.4) | 15 (10.2) |
| Cephazolin (n=180) | 9 (5.0) | 0 (0.0) | 171 (95) |
| Ceftriaxone (n=111) | 76 (68.5) | 1 (0.9) | 34 (30.6) |
| Cefotaxime (n=173) | 85 (49.1) | 0 (0.0) | 88 (50.9) |
| Ceftazidime (n=151) | 112 (74.2) | 0 (0.0) | 39 (25.8) |
| Cefepime (n=175) | 119 (68.0) | 2 (1.1) | 54 (30.9) |
| Ciprofloxacin (n=213) | 93 (43.7) | 77 (36.1) | 43 (20.2) |
| Levofloxacin (n=204) | 145 (71.1) | 39 (19.1) | 20 (9.8) |
| Imipenem (n=140) | 138 (98.6) | 0 (0.0) | 2 (1.4) |
Abbreviations: S, sensitive; R, resistant; I, intermediate.